Scienture revises Arena debenture conversion to $2.4861

Scienture Holdings, Inc. entered into a new letter agreement with Arena Finance Markets, LP and Arena Special Opportunities III LP to change key terms of its existing secured convertible debentures.

Rhea-AI Filing Summary

Scienture Holdings, Inc. entered into a new letter agreement with Arena Finance Markets, LP and Arena Special Opportunities III LP to change key terms of its existing secured convertible debentures. The parties agreed to amend the debentures so that any remaining amounts owed will convert into shares of Scienture common stock at a revised conversion price of $2.4861 per share, resulting in a full conversion of the debt into equity.

Once this full conversion occurs, the debentures and related transaction documents will be terminated, all obligations under those documents will be deemed fully satisfied, and all related security interests and liens held by the Arena investors will be automatically released. After that point, the Arena investors will have no further obligation to extend credit or provide other financial accommodations to Scienture under these arrangements.

Insights

Capital structure and credit analyst

Debt converts to equity at a set price, eliminating liens but ending this funding source.

The company and Arena investors agreed to revise the convertible debentures so that remaining amounts will convert into common stock at a $2.4861 per share conversion price. This turns existing secured debt into equity, changing the capital structure from a creditor relationship to a shareholder relationship for these investors and removing ongoing interest and principal obligations tied to the debentures.

Upon the full conversion, all obligations under the transaction documents are deemed paid, the debentures and related agreements terminate, and all security interests and liens in favor of the Arena investors are released. At the same time, the Arena investors will have no further obligation to provide credit extensions or financial accommodations to the company under these agreements, so future liquidity from this specific source will no longer be available. Subsequent disclosures may provide more detail on the resulting share count and overall balance sheet impact.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Scienture Holdings, Inc. (SCNX) change in its agreement with Arena investors?

Scienture Holdings, Inc. entered into a letter agreement with Arena Finance Markets, LP and Arena Special Opportunities III LP to amend its secured convertible debentures so that the remaining amounts owed will convert into common stock at a revised conversion price of $2.4861 per share.

What is the new conversion price for Scienture (SCNX) debentures held by Arena investors?

The company and the Arena investors agreed to revise the conversion price of the secured convertible debentures to $2.4861 per share of Scienture common stock.

What happens when the Scienture (SCNX) debentures are fully converted into common stock?

Upon the full conversion, all obligations under the transaction documents are deemed paid and discharged, the debentures and related documents are terminated, all security interests and liens in favor of the Arena investors are released, and the Arena investors will have no obligation to make further credit extensions or financial accommodations to the company.

Will Arena Finance Markets, LP and Arena Special Opportunities III LP continue lending to Scienture (SCNX)?

After the full conversion of the debentures into common stock, neither of the Arena investors will have any obligation to make additional credit extensions or financial accommodations to Scienture under these transaction documents.

How were the original Scienture (SCNX) debentures structured before this amendment?

Scienture previously issued 10% original issue discount secured convertible debentures to Arena Finance Markets, LP and Arena Special Opportunities III LP on November 25, 2024, which are now being amended to provide for full conversion into common stock at the revised price.

Does the amendment affect the security interests securing Scienture’s obligations to Arena investors?

Yes. Upon full conversion, all security interests, pledges and other liens granted to or held by the Arena investors as security for the obligations under the transaction documents will be terminated and automatically and irrevocably released.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:50 PM Learn about SEC filing dates

false 0001382574 0001382574 2025-10-03 2025-10-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 3, 2025

Scienture Holdings, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-39199		46-3673928
(State or other jurisdiction of incorporation)		(Commission File No.)		(I.R.S. Employer Identification No.)

20 Austin Blvd.

Commack, NY 11725

(Address of Principal Executive Offices)

(631) 670-6039

(Registrant’s Telephone Number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		SCNX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed, Scienture Holdings, Inc. (the “Company”) issued 10% original issue discount secured convertible debentures (the “Debentures”) to Arena Finance Markets, LP and Arena Special Opportunities III LP (the “Arena Investors”) on November 25, 2024.

On October 3, 2025, the Company entered into a letter agreement (the “Agreement”) with the Arena Investors whereby the Company and the Arena Investors agreed to amend Section 4(b) of the Debentures. Specifically, the Company and the Arena Investors agreed to revise the conversion price of the Debentures to $2.4861 per share. In addition, each of the Arena Investors agreed to convert the remaining amounts owed by the Company under the Debentures into shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) in accordance with the revised terms of the Debentures (the “Full Conversion”).

Pursuant to the Agreement, upon the Full Conversion, automatically and without any further action on the part of the Company or the Arena Investors: (i) all Obligations (as defined in the Security Agreement dated November 25, 2024, by and among the Company and the Arena Investors) under the Transaction Documents (as defined in the Securities Purchase Agreement dated November 22, 2024, by and among the Company and the Arena Investors (the “Purchase Agreement”)) will be deemed paid and will be automatically and irrevocably released, satisfied and discharged in full (except those obligations of the Company under Section 5.10 of the Purchase Agreement and Section 7 of the Registration Rights Agreement dated November 25, 2024, by and among the Company and the Arena Investors); (ii) the Debentures and all other Transaction Documents will be terminated; (iii) all security interests, pledges and other liens of every type at any time granted to or held by the Arena Investors as security for the Obligations or under any Transaction Document will be terminated and automatically and irrevocably released without further action by the Arena Investors; and (iv) neither of the Arena Investors will have any obligation to make any credit extensions or financial accommodations to the Company or any other obligations, duties, or responsibilities in connection therewith.

The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached hereto as Exhibit 10.1, and which is incorporated herein in its entirety by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
10.1		Letter Agreement dated October 2, 2025, by and among the Company, Arena Finance Markets, LP, and Arena Special Opportunities III LP
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SCIENTURE HOLDINGS, INC.
	By:	/s/ Dr. Narasimhan Mani
		Dr. Narasimhan Mani
		Co-Chief Executive Officer
Date: October 3, 2025